Early safety check: how a damaged liver handles an experimental drug
NCT ID NCT07049939
Summary
This early-stage study aimed to understand how a drug called bomedemstat (MK-3543) behaves in people with mild or moderate liver impairment. Researchers gave a single dose to 9 participants—some with liver problems and some healthy—and tracked the drug levels in their blood over time. The goal was to see if liver damage changes how the body processes the drug, which is important for future dosing and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Orlando Clinical Research Center ( Site 0001)
Orlando, Florida, 32809, United States
-
The Texas Liver Institute ( Site 0002)
San Antonio, Texas, 78215, United States
-
University of Miami ( Site 0003)
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.